News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Paladin Labs Inc. (CC:PLB) Expands Distribution Agreement with Shire Human Genetic Therapies HGT to Include ELAPRASE(TM) (Idursulfase)



8/9/2007 9:37:37 AM

MONTREAL, CANADA--(MARKET WIRE)--Aug 8, 2007 -- Paladin Labs Inc. (Toronto:PLB.TO - News), a leading Canadian specialty pharmaceutical company, today announced that it has expanded its current exclusive Canadian distribution agreement with Shire Human Genetic Therapies, Inc. (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ). Under the new agreement, Paladin will be distributing ELAPRASE(TM) (idursulfase) for Hunter syndrome in addition to REPLAGAL® (agalsidase alfa) for Fabry disease. Health Canada recently granted Shire HGT regulatory approval for ELAPRASE, indicated for enzyme replacement therapy in patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II).

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES